Back to Research News Research News and Information

2275 Swallow Hill Road - Building 2500 - Pittsburgh, PA 15220
(412) 429-0673 Fax: (412) 279-1367

Press Release


Pittsburgh, PA - February 18, 1997 - Biocontrol Technology, Inc. (NASDAQ:BICO) announced today that the Company held a press conference at 9:00 a.m. this morning at the Holiday Inn, Indiana, PA.

In his opening statement, Fred E. Cooper, chief executive officer of Biocontrol, stated that the conference was called to demonstrate the Company's Diasensor® 1000 noninvasive glucose sensor for diabetics and to explain its operation and how the sensor will affect those diabetics who can use it.

The Diasensor 1000 was submitted to the Food and Drug Administration (FDA) in January 1994 and is currently undergoing in-home testing.

Those in attendance saw the Diasensor 1000 measure the blood glucose levels of patients Patricia McAdams and George Hnatko, then saw those Diasensor readings compared to the glucose levels given by a standard laboratory reference device, the Yellow Springs Instrument (YSI). Ms. McAdams' glucose measured 230 mg/dL on the Diasensor 1000 and 228 mg/dL on the YSI. Mr. Hnatko's readings were 133 mg/dL on the Diasensor 1000 and 125 mg/dL on the YSI.

David L. Purdy, president and founder of Biocontrol, explained the Diasensor's operation, saying that the sensor is "an example of the most advanced state-of-the-art spectroscopy technology [which uses] the same principles ... to detect infrared light from a patient's arm ... as the space shuttle crew will install in the Hubble telescope to detect light from distant galaxies.

"[In the Diasensor 1000], the light emits from a fiberoptic probe, passes into the tissue, bounces back from inside the skin and is picked up by another fiberoptic element ... [that] carries the light to an optical component which separates it into its different wavelengths. By comparing the light to arm to the light collected from the arm, chemical compounds can be detected.

"Once we have separated the spectral characteristics of the energy," continued Mr. Purdy, "these wavelengths can be compared with those that have been previously measured from the patient at different levels of glucose in the patient's blood. Then a mathematical equation called an algorithm is applied to the information."

Mr. Purdy further explained, "To prepare the algorithm, [Biocontrol goes] through a calibration procedure in which the patient has a number of spectral measurements made at different glucose levels."

Todd Barker, Ph.D., the Company's manager of computational analysis, clarified that this spectral data is automatically converted into an algorithm by computers that use methods developed by a new discipline called chemometrics. Chemometrics utilizes multivariate analysis techniques to relate variables of measure, such as glucose and infrared spectra, to provide a mathematical relationship between the variables of interest.

Dr. Barker told members of the press that his algorithm is placed on a computer PCMCIA card which is inserted into the machine at use, and by each having his own PCMCIA card, a single Diasensor can be adapted for use by multiple members of the same family.

The Diasensor 1000 is 12" by 20.5", weights approximately 40 pounds (with the 17 pound powerpack), will have a two-year warranty, an expected life span of ten years, requires no supplies, could be equipped for use by the visually impaired, is anticipated to sell initially for US$7,950 when FDA approved, and will initially be available in the US by prescription only.

Acknowledging that "... the Diasensor 1000 is not perfect," Mr. Cooper said that "it's not yet for everyone and it's bigger and more expensive than we'd like it to be -- just like TVs were in the 40s, computers in the 60s and calculators in the 70s.... Those revolutionary products improved with continued research and development," he continued. "The Diasensor 1000 will, too."

The press conference concluded with a tour of Biocontrol's Manufacturing Center which has 22,500 square feet of completed and occupied space dedicated to manufacturing the Diasensor 1000. When additional space now under contruction is completed, manufacturing space will jump to 68,000 square feet.

Biocontrol Technology, Inc. has its corporate offices in Pittsburgh, PA and is involved in the development and manufacture of biomedical devices and environmental products.


  Back to Research News Return to the Top of This Page

Last Updated: Thursday February 27, 2014 19:28:21
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.